GlassScriptPhysician profile
Suha Kassab
NPI 1902890015
$2,981.47
in general payments reported to CMS, 2019-2025
28 companies · $192 in 2025
The $192 reported for 2025 was less than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $787 · 2020: $37.63 · 2021: $309 · 2022: $455 · 2023: $478 · 2024: $724 · 2025: $192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,393.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $451.24 | 2019-2025 | Stravix, Grafix Pl, Grafix |
| Aroa Biosurgery Incorporated | $284.34 | 2022-2024 | |
| Nevro Corp. | $222.95 | 2021-2022 | |
| Fusion Orthopedics USA, LLC | $208.43 | 2024 | |
| Paragon 28, INC. | $192.93 | 2019-2021 | |
| Abbvie INC. | $176.94 | 2024 | |
| Pinnacle, INC | $174.76 | 2019 | |
| Pfizer INC. | $161.17 | 2019 | |
| Convatec INC. | $143.35 | 2022-2024 | |
| Horizon Therapeutics Plc | $142.99 | 2023 | Krystexxa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $109.80 | 2023 | Trulance, Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $96.56 | 2023 | |
| Novo Nordisk INC | $82.56 | 2025 | Ozempic |
| Kci USA, INC. | $74.91 | 2023 | Promogran Prisma, Activ.A.C., V.A.C.Instill |
| Cardiovascular Systems INC. | $74.15 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $64.24 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $44.04 | 2024-2025 | Nuzyra |
| Amgen INC. | $36.84 | 2024-2025 | Krystexxa |
| Averitas Pharma INC. | $35.54 | 2023 | Qutenza |
| Integra Lifesciences Corporation | $34.81 | 2022 | |
| Grt US Holding, INC. | $31.69 | 2021-2022 | |
| Tactile Systems Technology INC | $30.01 | 2025 | Flexitouch Plus, Nimbl |
| Heron Therapeutics, INC. | $24.94 | 2021 | |
| Nabriva Therapeutics, Plc | $22.08 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $18.02 | 2023 | Seglentis |
| Linvatec Corporation | $16.96 | 2021 | |
| Reprise Biomedical, INC. | $12.90 | 2021 | |
| Zyla Life Sciences, INC. | $12.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suha Kassab listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.